查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197680

支原體檢測市場——增長、趨勢、COVID-19 影響和預測 (2023-2028)

Mycoplasma Testing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內，支原體檢測市場預計將以 13% 的複合年增長率穩步增長。

最近，各國都面臨著 COVID-19 的巨大威脅。 根據世界衛生組織（WHO）的說法，冠狀病毒病是一種傳染病，大多數人在感染 COVID-19 病毒後會出現輕度至中度的呼吸道疾病。 2022 年 4 月發表的一項名為“COVID-19 大流行之前和期間北京兒童肺炎支原體流行情況”的研究指出，肺炎球菌流行於 2019 年夏季在北京開始。 在 2019 年底爆發 COVID-19 大流行之後，肺炎支原體流行率急劇下降。 這是因為 COVID-19 大流行的限制措施有效地抑制了肺炎支原體的傳播。 然而，在放鬆對 COVID-19 的管制後，肺炎支原體預計在研究期間將進一步增加，從而影響市場增長。

生物製藥公司在研發活動上的高支出、政府對研究活動的承諾和資助的增加、技術進步、對快速、準確和廉價測試的需求增加、細胞培養物污染增加等因素進一步推動了支原體檢測市場.

在 2021 年 10 月發表的“使用淬滅探針聚合□鏈反應對大環內酯敏感性進行肺炎支原體即時分子診斷”的研究中，Smart Gene 系統能夠檢測到肺炎支原體的存在以及肺炎支原體的 23S rRNA肺炎支原體。它被描述為一種快速準確的檢測方法，用於同時檢測基因域 V 中的點突變。 Smart Gene 系統適用於醫院和門診即時檢測。 因此，此類研究展示了肺炎支原體的潛在診斷測試，將擴大其接受度並推動市場。

2022 年 4 月，Alpha Biolabs 推出了面向公眾和醫療保健合作夥伴的 STI 測試。 The Complete Panel (7 STIs) detects Chlamydia, Gonorrhea, Mycoplasma genitalium, Mycoplasma hominis, Trichomonas, Ureaplasma parvum (UTI), and Urea urealyticum (UTI) bacteria. Detects urea urea, trichomonas (UTI) 細菌。 因此，檢測支原體細菌的檢測試劑的推出將提振市場。 因此，由於上述因素，該研究涵蓋的市場預計在研究期間將顯著增長。 然而，多個發達國家和新興國家都有一定的嚴格政府法規，新進入者的高度整合是支原體檢測市場增長的主要製約因素之一。

支原體檢測市場趨勢

聚合□鏈反應 (PCR) 預計在預測期內將佔據重要的市場份額

北美目前在支原體檢測市場佔據主導地位，預計未來幾年仍將如此。 由於該地區完善的醫療保健行業和呼吸系統疾病患病率上升，預計該地區未來的市場份額將增加。 其他增長因素包括全球生物技術和製藥公司的存在以及該地區研發活動投資的增加。 在北美，美國占據了大部分市場份額。 這是由於即時檢測的迅速採用以及不斷上升的醫療保健成本。

此外，該產品在該國的推出將增加支原體檢測程序，促進市場增長。 例如，2020 年 7 月，生物梅裡埃針對生物治療藥物（抗體、激素、細胞和基因治療等）中使用的藥物（抗體、激素、細胞和基因治療等）推出了支原體檢測的創新測試，這是製藥行業最具活力的領域之一。藥物“BIOFIRE MYCOPLASMA ”在美國推出。 此外，2020 年 4 月，Infinity Laboratories 啟動了支原體檢測並擴展了其能力。 這種關鍵戰略的採用，如擴張、合作夥伴關係和收購，擴大了主要市場參與者的能力，從而推動了市場增長。

此外，越來越多的研發研究證明了美國診斷技術的有效性，預計將在研究期間推動市場增長。 例如，2021 年 1 月，富士膠片和先進生物創新與製造中心將在馬薩諸塞州投資約 7600 萬美元，用於細胞和基因治療、基因編輯、免疫治療和生物技術領域的先進研發工作。 因此，由於上述因素，預計研究期間該地區的市場將顯著增長。

預計在預測期內北美將佔據重要的市場份額

北美目前在支原體檢測市場佔據主導地位，預計未來幾年仍將保持主導地位。 由於成熟的醫療保健行業和呼吸系統疾病患病率上升，預計該地區的市場份額將增加。 其他增長因素包括全球生物技術和製藥公司的存在以及該地區研發活動投資的增加。 在北美，美國占據了大部分市場份額。 這是由於即時檢測的迅速採用以及不斷上升的醫療保健成本。

此外，該產品在該國的推出將增加支原體檢測程序，促進市場增長。 例如，2020 年 7 月，生物梅裡埃推出了一項創新測試，用於檢測生物治療藥物（抗體、激素、細胞和基因療法等）中使用的支原體，這是製藥行業最具活力的領域之一。“BIOFIRE 支原體”在美國發售。

此外，2020 年 4 月，Infinity Laboratories 開始測試支原體並擴展其能力。 擴張、合作夥伴關係和收購等關鍵戰略的採用擴大了主要市場參與者的能力，從而推動了市場增長。

此外，在美國不斷增加的研發證明診斷技術的有效性預計將在研究期間推動市場增長。 例如，根據 2020 年 5 月發表的“檢測和測定肺炎支原體大環內酯耐藥性的商業分子診斷方法評估”研究，InGenius PCR (99.5%) 和 FilmArray RP (98.1%) 顯示臨床敏感性最高確認的。 因此，日本有效診斷技術的存在有望推動支原體檢測並最終推動市場發展。 因此，由於上述因素，預計研究期間該地區的市場將顯著增長。

支原體檢測市場競爭對手分析

市場競爭適中。 公司正在專注於各種增長戰略，例如新產品發布、聯盟、收購和合作夥伴關係，以增加他們的市場佔有率。 主要參與者包括 Abbott、Agilent Technologies、Charles River Laboratories International Inc.、Eurofins Scientific、F. Hoffmann-La Roche Ltd、Lonza Group、Merck KGaA、PromoCell GmbH、Sartorius AG 和 Thermo Fisher Scientific Inc. 等公司。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 增加政府對研究活動的承諾和資助
    • 對快速、準確且經濟實惠的測試的需求增加
    • 細胞培養污染增加
  • 市場製約因素
    • 漫長而費力的檢查過程
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：單位：百萬美元）

  • 按產品分類
    • 樂器
    • 試劑盒和試劑
  • 按技術
    • 聚合□鏈反應
    • ELISA 方法
    • □法
    • DNA 染色
    • 其他技術
  • 通過申請
    • 細胞系檢測
    • 生物生產測試
    • 其他應用
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Agilent Technologies
    • ATCC
    • Bionique Testing Laboratories Inc.
    • Charles River Laboratories International Inc.
    • Eurofins Scientific
    • Lonza Group Ltd
    • Merck KGaA
    • Bionique Testing Laboratories Inc.
    • PromoCell GmbH
    • Thermo Fisher Scientific Inc.
    • AdvaCare
    • Sartorius AG

第7章 市場機會與今後動向

簡介目錄
Product Code: 51949

The mycoplasma testing market is estimated to register a healthy CAGR of 13% over the forecast period, 2022-2027.

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. The study "The Prevalence of Mycoplasma Pneumoniae Among Children in Beijing Before and During the COVID-19 Pandemic" published in April 2022, stated that the M. pneumoniae outbreak started in the summer of 2019 in Beijing. After the COVID-19 pandemic outbreak at the end of 2019, the M. pneumoniae positive rates dropped dramatically. This was due to the restrictive measures of the COVID-19 pandemic, which effectively controlled the transmission of M. pneumonia. However, after the easing of COVID-19 restrictions, M. pneumonia is expected to increase further during the study period, thereby impacting the market growth.

Factors such as high spending in R&D activities by biopharmaceutical companies, increased government initiatives and funding in research activities, technological advancements, increasing demand for fast, accurate, and affordable testing, and the increasing cell culture contamination, are further driving the market for mycoplasma testing.

The study "Point-of-care molecular diagnosis of Mycoplasma pneumonia including macrolide sensitivity using quenching probe polymerase chain reaction" published in October 2021, stated that the Smart Gene system is a rapid and accurate assay for detection of the existence of M. pneumoniae and a point mutation at domain V of the 23S rRNA gene of M. pneumoniae at the same time. The Smart Gene system is suitable for point-of-care testing in both hospital and outpatient settings. Thus, such studies indicating the potential of diagnostic testing for mycoplasma pneumonia will increase their acceptance, thus driving the market.

In April 2022, AlphaBiolabs launched STI testing for members of the public and healthcare partners. The Complete Panel (7 STIs) detects chlamydia, gonorrhea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, and ureaplasma parvum (UTI), and urea urealyticum (UTI) bacterias. Therefore, the launch of such tests detecting mycoplasma bacteria will boost the market. Thus, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period. However, there are certain stringent government regulations across several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major hindrances in the growth of the mycoplasma testing market.

Mycoplasma Testing Market Trends

Polymerase Chain Reaction (PCR) is Expected to Hold a Significant Market Share Over the Forecast Period

North America currently dominates the mycoplasma testing market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future due to its well-established healthcare industry and the rising prevalence of respiratory diseases in the area. Other factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region. The United States holds the majority of the market share in North America. This is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

The launch of products in the country will also increase the mycoplasma testing procedures contributing to the market growth. For instance, in July 2020, bioMerieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in the United States for pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry. Furthermore, in April 2020, Infinity Laboratories expanded its capabilities by launching Mycoplasma testing. Such adoption of critical strategies like expansion, partnerships, acquisitions, and others will expand the capabilities of the key market players, thereby driving the market growth.

Moreover, rising research and development studies proving the efficacies of diagnostic techniques in the United States are expected to drive market growth during the study period. For instance, in January 2021, Fujifilm and the Center for Advanced Biological Innovation and Manufacturing are investing about USD 76 million in Massachusetts for advanced research and development in cell and gene therapy, gene editing, immunotherapy, and biotechnology. Thus, owing to the above-mentioned factors, the studied market is expected to grow significantly in the region during the study period.

North America is Expected to Occupy a Significant Market Share Over the Forecast Period

North America currently dominates the mycoplasma testing market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share due to its well-established healthcare industry and the rising prevalence of respiratory diseases. Other factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region. The United States holds the majority of the market share in North America. This is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

Launching products in the country will also increase the mycoplasma testing procedures contributing to the market growth. For instance, in July 2020, bioMerieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in the United States for pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry.

Furthermore, in April 2020, Infinity Laboratories expanded its capabilities by launching Mycoplasma testing. Such adoption of key strategies like expansion, partnerships, acquisitions, and others will expand the capabilities of the key market players, thereby driving market growth.

Moreover, rising research and development studies proving the efficacies of diagnostic techniques in the United States are expected to drive market growth during the study period. For instance, according to the study "Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumonia" published in May 2020, the highest clinical sensitivities were found with the InGenius PCR (99.5%) and the FilmArray RP (98.1%). Therefore, the presence of effective diagnostic techniques in the country is expected to boost mycoplasma testing and, in turn, is expected to drive the market. Thus, owing to the factors mentioned above, the studied market is expected to grow significantly in the region during the study period.

Mycoplasma Testing Market Competitor Analysis

The studied market is moderately competitive. Companies are focusing on various growth strategies, such as new product launches, collaborations, acquisitions, and partnerships, to enhance their market presence. The major players include Abbott, Agilent Technologies, Charles River Laboratories International Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Lonza Group, Merck KGaA, PromoCell GmbH, Sartorius AG, and Thermo Fisher Scientific Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Government Initiatives and Funding in Research Activities
    • 4.2.2 Increasing Demand for Fast, Accurate, and Affordable Testing
    • 4.2.3 Increasing Cell Culture Contamination
  • 4.3 Market Restraints
    • 4.3.1 Long and Laborious Detection Process
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Instruments
    • 5.1.2 Kits and Reagents
  • 5.2 By Technology
    • 5.2.1 PCR
    • 5.2.2 ELISA
    • 5.2.3 Enzymatic Methods
    • 5.2.4 DNA Staining
    • 5.2.5 Other Technologies
  • 5.3 By Application
    • 5.3.1 Cell Line Testing
    • 5.3.2 Bioproduction Testing
    • 5.3.3 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 ATCC
    • 6.1.3 Bionique Testing Laboratories Inc.
    • 6.1.4 Charles River Laboratories International Inc.
    • 6.1.5 Eurofins Scientific
    • 6.1.6 Lonza Group Ltd
    • 6.1.7 Merck KGaA
    • 6.1.8 Bionique Testing Laboratories Inc.
    • 6.1.9 PromoCell GmbH
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 AdvaCare
    • 6.1.12 Sartorius AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS